A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765
NCT ID: NCT01130909
Last Updated: 2014-10-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
36 participants
INTERVENTIONAL
2010-05-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers
NCT04928703
Investigating the Role and Electrophysiological Characteristics of the Human Claustrum Based on SEEG
NCT06575413
Cortical Excitability and Treatment Response in People with Epilepsy
NCT05551403
Modulation of Emotion Perception in Humans Via Amygdala Stimulation
NCT05292183
PET/MRI/EEG Imaging Study in Epilepsy
NCT06974305
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AZD6765 75 mg
AZD6765
75 mg
AZD6765 150 mg
AZD6765
150 mg
Ketamine 0.5 mg/kg
Ketamine
0.5 mg/kg
125 mL sterile NaCl 0.9%
Placebo
125 mL sterile NaCl 0.9%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD6765
75 mg
AZD6765
150 mg
Ketamine
0.5 mg/kg
Placebo
125 mL sterile NaCl 0.9%
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* History of substance abuse Hypersensitivity to ketamine
30 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Albena Patroneva, MD
Role: STUDY_DIRECTOR
AstraZeneca
Francine Santoro
Role: PRINCIPAL_INVESTIGATOR
Forenap
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Rouffach, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014 Sep;19(9):978-85. doi: 10.1038/mp.2013.130. Epub 2013 Oct 15.
Related Links
Access external resources that provide additional context or updates about the study.
D2285M00008 Clinical Study Report Synopsis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D2285M00008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.